Corbus Pharmaceuticals (CRBP) Given Media Sentiment Score of 0.09

Media headlines about Corbus Pharmaceuticals (NASDAQ:CRBP) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corbus Pharmaceuticals earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.3646488138386 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Corbus Pharmaceuticals stock opened at $7.10 on Monday. Corbus Pharmaceuticals has a twelve month low of $5.30 and a twelve month high of $10.50. The firm has a market cap of $405.66, a PE ratio of -10.92 and a beta of 2.09.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its earnings results on Monday, March 12th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.04). Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 75.88%. analysts forecast that Corbus Pharmaceuticals will post -0.81 EPS for the current year.

Several analysts recently commented on CRBP shares. Cantor Fitzgerald set a $28.00 price objective on shares of Corbus Pharmaceuticals and gave the company an “overweight” rating in a research note on Thursday, December 14th. Noble Financial restated a “buy” rating on shares of Corbus Pharmaceuticals in a report on Friday, December 15th. BidaskClub downgraded shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Raymond James Financial began coverage on shares of Corbus Pharmaceuticals in a report on Friday, January 19th. They set an “outperform” rating and a $24.00 target price for the company. Finally, ValuEngine upgraded shares of Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $25.75.

In other Corbus Pharmaceuticals news, Director David P. Hochman bought 5,000 shares of the company’s stock in a transaction on Wednesday, March 14th. The stock was purchased at an average cost of $6.67 per share, for a total transaction of $33,350.00. Following the acquisition, the director now owns 459,500 shares of the company’s stock, valued at approximately $3,064,865. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired a total of 12,145 shares of company stock valued at $81,680 over the last 90 days. 11.90% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply